Skip to content

Versant Venture Management, LLC

Follow

13F filer, CIK 1560009, San Francisco, CA

Versant Venture Management, LLC reported $109,097,271 across 8 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-13.

Accepted , ingested 13F-HR 0001193125-26-460919

Period
2026-09-30
Reported value
$109M
Holdings
8
Top 10 weight
100%
New
1
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CTNMadded+750,000$10.1M
SKYEnew+250,962$404K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
SKYEexited-2,007,704-$1.39M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001193125-26-460919, largest first. % of portfolio is the value over $109,097,271, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 5,652,922 shares; 2025Q1: 5,652,922 shares; 2025Q2: 5,652,922 shares; 2025Q3: 5,652,922 shares; 2025Q4: 4,382,687 shares; 2026Q1: 3,180,780 shares; 2026Q2: 3,180,780 shares; 2026Q3: 3,180,780 shares 3,180,780$37.9M34.78%0Timeline
IPSCCENTURY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 12,166,109 shares; 2026Q2: 12,166,109 shares; 2026Q3: 12,166,109 shares 12,166,109$20.8M19.07%0Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 918,163 shares; 2025Q1: 918,163 shares; 2025Q2: 542,628 shares; 2025Q3: 542,628 shares; 2025Q4: 542,628 shares; 2026Q1: 542,628 shares; 2026Q2: 542,628 shares; 2026Q3: 1,292,628 shares 1,292,628$17.3M15.9%+750,000Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,525,820 shares; 2025Q3: 1,525,820 shares; 2025Q4: 1,525,820 shares; 2026Q1: 1,525,820 shares; 2026Q2: 991,783 shares; 2026Q3: 991,783 shares 991,783$13.9M12.77%0Timeline
LENZLENZ THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,656,888 shares; 2025Q4: 2,656,888 shares; 2026Q1: 2,656,888 shares; 2026Q2: 2,656,888 shares; 2026Q3: 2,656,888 shares 2,656,888$10.2M9.35%0Timeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 498,558 shares; 2025Q1: 498,558 shares; 2025Q2: 498,558 shares; 2025Q3: 148,831 shares; 2025Q4: 148,831 shares; 2026Q1: 148,831 shares; 2026Q2: 148,831 shares; 2026Q3: 148,831 shares 148,831$8.23M7.55%0Timeline
SKYESKYE BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 250,962 shares 250,962$404K0.37%newTimeline
TEMPEST THERAPEUTICS INCTEMPEST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,507,055 shares; 2025Q1: not reported; 2025Q2: 269,772 shares; 2025Q3: 269,772 shares; 2025Q4: 269,772 shares; 2026Q1: 269,772 shares; 2026Q2: 269,772 shares; 2026Q3: 269,772 shares 269,772$225K0.21%0

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SKYESKYE BIOSCIENCE INC2,007,704$1.39Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-460919 base2026-11-13